Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

TaiGen Biopharmaceuticals Holdings Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Philip Huang

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	5.8yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	13.2yrs
Yönetim Kurulu ortalama görev süresi	11.5yrs

Son yönetim güncellemeleri

Recent updates

Here's Why We're Not Too Worried About TaiGen Biopharmaceuticals Holdings' (GTSM:4157) Cash Burn Situation

Apr 19

We're Not Very Worried About TaiGen Biopharmaceuticals Holdings' (GTSM:4157) Cash Burn Rate

Jan 04

CEO

Philip Huang

5.8yrs

Görev süresi

Mr. Kuo-Lung Huang, also known as Philip, serves as General Manager of TiaGen BioPharmaceuticals Co. (Beijing), Ltd. Mr. Huang is Chairman of the Board, President & Chief Executive Officer at TaiGen Biotec...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ming-Chu Hsu	Founder	23.8yrs	NT$15.00k	Veri yok
Kuo-Lung Huang	Chairman of the Board	no data	Veri yok	Veri yok
Richard Lu	Vice President of Finance	8.5yrs	Veri yok	Veri yok
Mark Kao	Head of the Accounting Department	no data	Veri yok	Veri yok
Peter Tsao	Vice President Corporate Development	13.2yrs	Veri yok	Veri yok

13.2yrs

Ortalama Görev Süresi

Deneyimli Yönetim: 4157 'un yönetim ekibi deneyimli ve deneyimlidir ( 13.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Kuo-Lung Huang	Chairman of the Board	5.8yrs	Veri yok	Veri yok
Ye-Hong Zhang	Independent Director	5.3yrs	Veri yok	Veri yok
Show-Chung Ho	Director	11.5yrs	NT$123.00k	Veri yok
Hong-Jen Chang	Director	14.3yrs	NT$135.00k	Veri yok
Kuo-Hsi Wang	Director	15.6yrs	NT$135.00k	Veri yok
Shen-Fu Yu	Independent Director	5.3yrs	Veri yok	Veri yok
Chiung-Feng Ko	Supervisor	12.3yrs	NT$135.00k	Veri yok
Shih-Jen Hsiao	Supervisor	11.5yrs	NT$120.00k	Veri yok
Ta-Shao Shih	Supervisor	9.3yrs	Veri yok	Veri yok
Peter Wu	Director	no data	Veri yok	Veri yok
Weng-Foung Huang	Independent Director	no data	Veri yok	Veri yok
Chi-Kung Ho	Director	no data	Veri yok	Veri yok

11.5yrs

Ortalama Görev Süresi

69.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 4157 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 11.5 yıldır).

TaiGen Biopharmaceuticals Holdings Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

TaiGen Biopharmaceuticals Holdings Limited, Annual General Meeting, May 29, 2024

Less than half of directors are independent

Less than half of directors are independent

TaiGen Biopharmaceuticals Holdings Limited, Annual General Meeting, May 27, 2021

Recent updates

Second quarter 2024 earnings released: EPS: NT$0.09 (vs NT$0.014 in 2Q 2023)

First quarter 2024 earnings released: NT$0.01 loss per share (vs NT$0.07 loss in 1Q 2023)

Full year 2023 earnings released: EPS: NT$0.19 (vs NT$0.33 loss in FY 2022)

TaiGen Biopharmaceuticals Holdings Limited, Annual General Meeting, May 29, 2024

Third quarter 2023 earnings released: NT$0.01 loss per share (vs NT$0.015 profit in 3Q 2022)

Second quarter 2023 earnings released: EPS: NT$0.015 (vs NT$0.14 loss in 2Q 2022)

Full year 2022 earnings released: NT$0.33 loss per share (vs NT$1.08 profit in FY 2021)

Third quarter 2022 earnings released: EPS: NT$0.02 (vs NT$0.20 loss in 3Q 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: NT$0.02 (vs NT$0.20 loss in 3Q 2021)

Second quarter 2022 earnings released: NT$0.14 loss per share (vs NT$1.54 profit in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings released: NT$0.05 loss per share (vs NT$0.061 loss in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: NT$1.08 (vs NT$0.56 loss in FY 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: NT$0.19 loss per share (vs NT$0.14 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS NT$1.54 (vs NT$0.14 loss in 2Q 2020)

First quarter 2021 earnings released: NT$0.06 loss per share (vs NT$0.10 loss in 1Q 2020)

Here's Why We're Not Too Worried About TaiGen Biopharmaceuticals Holdings' (GTSM:4157) Cash Burn Situation

Full year 2020 earnings released: NT$0.56 loss per share (vs NT$0.41 loss in FY 2019)

TaiGen Biopharmaceuticals Holdings Limited, Annual General Meeting, May 27, 2021

New 90-day low: NT$17.90

New 90-day low: NT$21.35

We're Not Very Worried About TaiGen Biopharmaceuticals Holdings' (GTSM:4157) Cash Burn Rate

TaiGen Biotechnology Company, Limited Partners with GPCR Therapeutics, Inc. to Develop Burixafor & Taigexyn(R)

Third quarter 2020 earnings released: NT$0.14 loss per share

First half earnings released

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş